16th UC SAN DIEGO MOORES CANCER CENTER

INDUSTRY/Academia
Next Generation Precision Oncology Symposium

Thursday February 20, 2020
8AM - 6PM
Goldberg Auditorium
Moores Cancer Center
La Jolla, California

www.ucsdmccindustryrelations.org
16th UC SAN DIEGO MOORES CANCER CENTER
INDUSTRY/ACADEMIA
NEXT GENERATION PRECISION ONCOLOGY SYMPOSIUM

THURSDAY FEBRUARY 20, 2020  |  8AM - 6PM
MOORES CANCER CENTER  |  LA JOLLA, CALIFORNIA

Symposium Organizer
Ida Deichaite, PhD
Director, Industry Relations,
Moores Cancer Center
Assistant Adjunct Professor
UC San Diego

Symposium Organizer
Scott Lippman, MD
Director, Moores Cancer Center
Distinguished Professor of Medicine
Senior Associate Dean and Associate Vice
Chancellor, Cancer Research and Care
UC San Diego

Session Chair: Immuno-Oncology
Ezra Cohen, MD, FRCPC, FASCO
Chief, Division of Hematology/Oncology,
Department of Medicine
Co-Director, San Diego Center for Precision
Immunotherapy,
Associate Director for Translational Science,
Moores Cancer Center, UC San Diego

Session Chair: Solid Tumors
J. Silvio Gutkind, PhD
Distinguished Professor of Pharmacology
Associate Director of Basic Science,
Moores Cancer Center
Co-Director, Head and Neck Cancer Center
UC San Diego

Session Chair: Hematology/Oncology
Catriona Jamieson, MD, PhD
Professor of Medicine, Division of Hematology-Oncology
Deputy Director, Moores Cancer Center
Koman Family Presidential Endowed Chair
in Cancer Research
Chief, Division of Regenerative Medicine
Deputy Director, Sanford Stem Cell Clinical Center
UC San Diego

PAGE 1
BIOGRAPHIES

Keynote Speakers

Arie Beldegrun, MD, FACS
Professor, Director of the UCLA Institute of Urologic Oncology
Director of UCLA Urologic Research in the Department of Urology
Clinical Director of UCLA Prostate Disease Research Programs
Surgical Director of UCLA Kidney Cancer Program

Arie Beldegrun, MD, is currently Director of the UCLA Institute of Urologic Oncology, at the David Geffen School of Medicine at UCLA, Professor of Urology and Chief of the Division of Urologic Oncology. As director, Dr. Beldegrun is responsible for leading a multidisciplinary team of scientists and physicians, ranging in disciplines from medical oncology to nursing, to work together to personalize patient care and develop revolutionary treatments for varying types of cancers.

A visionary entrepreneur, Dr. Beldegrun had been closely involved in the development and founding of numerous successful biopharmaceutical companies including Aliogene Therapeutics and Kite Pharma Inc., a biopharmaceutical company engaged in the development of innovative cancer immunotherapies. He has served as Chairman at UroGen Bio, Teva Pharmaceuticals, Kronos Bio Inc., and was Founding Vice-Chairman of Cougar Biotechnology. In addition, Dr. Beldegrun is the author of several books on prostate and kidney cancers and has written over 250 scientific publications with an emphasis on urologic oncology, particularly kidney, prostate and bladder cancers.

He earned his medical degree at the Hebrew University Hadassah Medical School in Jerusalem and completed his residency in Urology at Harvard Medical School. Prior to UCLA, Dr. Beldegrun was a research fellow at the National Cancer Institute.

2020 Duane Roth Achievement Award Lecture
Scott Gottlieb, MD
Board of Directors, Pfizer
AEI Resident Fellow
NEA Partner

Scott Gottlieb, MD, a physician and medical policy expert, is a Special Partner of New Enterprise Associations, Inc.’s healthcare investment team and a Resident Fellow of the American Enterprise Institute. He most recently joined Pfizer’s Board of Directors this year after serving as the 23rd Commissioner of the FDA and Deputy Commissioner for Medical and Scientific Affairs. At the FDA, Dr. Gottlieb focused on a wide variety of issues, including drug pricing, medical product innovation, food safety, vaccination, and tobacco and vaping. He advanced new policies to address opioid addiction, working to rationalize prescribing to reduce the rate of new addiction.

Dr. Gottlieb has held several roles in the public and private sectors including serving as an elected member of the National Academy of Medicine and a Senior Advisor to the Administrator of the Centers for Medicare and Medicaid Services, where he helped implement the Medicare drug benefit and promote the effective use of new medical technologies. Overall, his work focuses on advancing public health through developing and implementing innovative approaches to improving medical outcomes, reshaping healthcare delivery, and expanding consumer choice and safety. Dr. Gottlieb is widely published in leading medical journals and periodicals, including The Wall Street Journal, The New York Times, and The Washington Post. He has held editorial positions on the British Medical Journal and the Journal of the American Medical Association and appears regularly as a guest commentator on CNBC.

Early in his career, Dr. Gottlieb was a practicing hospitalist and a Clinical Professor at the New York University School of Medicine. He completed a residency in internal medicine at the Mount Sinai Medical Center in New York and is a graduate of the Mount Sinai School of Medicine and of Wesleyan University, in Middletown, Connecticut, where he studied Economics.

PAGE 3
Symposium Organizers

Ida Deichaithe, PhD  
*Director, Industry Relations, Moores Cancer Center  
Assistant Adjunct Professor, Department of Radiation Medicine and Applied Sciences, UC San Diego*

Dr. Ida Deichaithe oversees the translational aspects of oncology at MCC, turning innovation into commercial applications. Her work with industry on behalf of MCC conferred competitive advantages to a CIRM Disease Team grant, securing $20 million in funding for an early stage biologic development leading to a clinical trial. This resulted in IND for a first in class biologic drug agent targeting cancer stem cells. Her successful partnering with pharma includes overseeing strategy and execution of translational collaborations between academia and industry, pre-clinical and clinical alliances, and due diligence.

Dr. Deichaithe is an Assistant Adjunct Professor in the Department of Radiation Medicine and Applied Sciences. Her research interests include cancer genomics.

She is Section Editor of Science Policy and Industry/Academia Interface of the Journal of Translational Medicine. Dr. Deichaithe is widely published in numerous scientific journals. Dr. Deichaithe received her Ph.D. from Princeton University, Masters degree from the Weizmann Institute, and BA from Hebrew University.

Scott Lippman, MD  
*Director, Moores Cancer Center  
Distinguished Professor of Medicine  
Senior Associate Dean and Associate Vice Chancellor, Cancer Research and Care  
UC San Diego*

Scott M. Lippman, MD, is director of Moores Cancer Center at UC San Diego Health, distinguished professor of Medicine at UC San Diego School of Medicine, senior associate dean and associate vice chancellor for Cancer Research and Care and holds the Chugai Pharmaceutical Chair in Cancer. He is also an adjunct professor at the Salk Institute, the Sanford-Burnham Medical Research Institute and MD Anderson Cancer Center.

Dr. Lippman has been recognized in every major “Top Doctor” listing, including U.S. News & World Report. He has received numerous awards, including the American Cancer Society of Clinical Oncology (ASCO) Award, the American Association for Cancer Research (AACR) Award and the ASCO Statesman Award.

Dr. Lippman brings more than 30 years of experience as principal investigator of translational research involving investigator-initiated clinical trials. He has participated in the national leadership of clinical/translational research planning and development within the National Cancer Institute Cooperative Group setting and currently serves on the National Cancer Institute’s Clinical Trials and Translational Research Advisory Committee. He is also a member of the Board of Directors for the AACR, the Association of American Cancer Institutes and the National Comprehensive Cancer Network and has served on the FDA Oncologic Drugs Advisory Committee. Dr. Lippman is an elected member of the prestigious Association of American Physicians.

He has authored more than 400 publications in high-impact journals, including The New England Journal of Medicine, the Journal of the American Medical Association, the Proceedings of the National Academy of Sciences and The Lancet, and chapters in major medical textbooks.

Before joining UC San Diego Health, he was chair of the Department of Thoracic/Head and Neck Medical Oncology at MD Anderson Cancer Center.

Dr. Lippman completed fellowships in hematology and medical oncology at Stanford University and the University of Arizona. He completed an internship and residency training in internal medicine at The Johns Hopkins Hospital and Harbor-UCLA Medical Center. He received his medical degree from The Johns Hopkins University School of Medicine. He is board-certified in internal medicine, hematology and medical oncology.
Symposium Session Chairs

Session: Immuno-Oncology
Ezra Cohen, MD, FRCPC, FASCO
Chief, Division of Hematology/Oncology, Department of Medicine  
Co-Director, San Diego Center for Precision Immunotherapy  
Associate Director for Translational Science, Moores Cancer Center  
UC San Diego

Ezra Cohen, MD, is co-Director of the San Diego Center for Precision Immunotherapy and an internationally renowned translational researcher. A physician-scientist, Dr. Cohen led an independently funded laboratory interested in mechanisms of action of novel therapeutics. He has made major contributions to targeted and immunotherapy. His research has received peer-reviewed funding in the study of epidermal growth factor receptor inhibitors, cell therapy, and immunotherapy in head and neck cancer. He has made major contributions to the understanding of critical signaling pathways, integration of novel agents into standard of care, and definition of mechanisms to overcome resistance to drug therapy. He has also recently co-developed a personalized neoantigen vaccine using unique cancer mutations to boost an anti-tumor immune response.

Dr. Cohen is Associate Director for Translational Science and leader of the Solid Tumor Therapeutics research program at Moores Cancer Center. He brings his expertise and preeminent reputation in head and neck cancer research and patient care to solid tumor therapeutics. Among other roles, he is chair of the Protocol Review and Monitoring Committee (PRMC) and serves as a member of the Cancer Council, and the Cancer Center's Executive Committee.

Dr. Cohen recently served as editor-in-chief of Oral Oncology, the highest impact specialty journal in head and neck cancer, and currently serves as senior editor for Clinical Cancer Research. He has been the principal investigator on multiple studies of novel agents in head and neck cancer and other solid tumors in all phases of development including chemoprevention, phase I, II, and III trials. Dr. Cohen has authored more than 170 papers and has presented his research at national and international meetings. In addition, he has served as a grant reviewer for the NIH, American Association for Cancer Research, American Society of Clinical Oncology, and the Ontario Institute for Cancer Research.

Dr. Cohen completed residencies in Family Medicine at the University of Toronto and in Internal Medicine at Albert Einstein College of Medicine. He completed a Hematology/Oncology fellowship at the University of Chicago where he was named chief fellow. Prior to his arrival in San Diego, Dr. Cohen was Co-Director of the Head and Neck Cancer Program, Associate Director for Education and Program Director for the Hematology/Oncology Fellowship at the University of Chicago Comprehensive Cancer Center. A dedicated educator, Dr. Cohen also mentored and developed young faculty in his program.

Session: Solid Tumors
J. Silvio Gutkind, PhD
Distinguished Professor of Pharmacology  
Associate Director of Basic Science, Moores Cancer Center  
Co-Director, Head and Neck Cancer Center  
UC San Diego

J. Silvio Gutkind, Ph.D., is a basic scientist with a passion for exploiting the emerging information on dysregulated signaling circuits and individual genomic and molecular alterations to develop new precision therapies to prevent and treat cancer. His laboratory has focused on the study of growth-promoting signal transduction pathways, the nature of the dysregulated signaling networks in cancer, and on the use of genomic, proteomic, and system biology approaches to study cancer initiation and progression. Specifically, they have shown that human and virally-encoded G proteins and G protein coupled receptors (GPCRs) can display potent oncogenic activity. Emerging evidence from his laboratory has revealed that malignant cells often hijack the normal physiological functions of GPCRs to proliferate autonomously, evade immune detection, enhance their nutrient and oxygen supply, invade their surrounding tissues, and disseminate to other organs. Strikingly, their recent analysis of human cancer genomes revealed an unanticipated high frequency of mutations in G proteins and GPCRs in most tumor types. Indeed, nearly 30% of all human cancers harbor mutations in GPCRs or G proteins. His lab is now investigating the mechanisms by which genetic mutations in Gαq proteins initiate uveal and cutaneous melanoma, the role of Gαs and its target, PKA, in cancer, with emphasis on colorectal cancer, and how mutations and autocrine activation of GPCRs contribute to tumor progression, immune evasion, and therapy resistance. In parallel, they are exploring the role of the mTOR pathway in head and neck cancer, a disease that results in 250,000 deaths each year worldwide. Based on their
studies, and emerging results from their multi-institutional clinical trial targeting mTOR in oral cancer, they are now investigating the effectiveness and mechanism of action of PI3K/mTOR inhibitors for oral cancer prevention and treatment, as single agents and as part of novel signal transduction-based co-targeting strategies. Dr. Gutkind has led a national and international effort addressing oral and head and neck malignancies as the Chief of the Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research, and as a leader of a NCI/trans-NIH program in oral cancer research, from 1998 until the recent relocation of his research team to the University of California San Diego (UCSD) Department of Pharmacology and Moores Cancer Center in September, 2015. He is currently a Distinguished Professor of Pharmacology and the Associate Director of Basic Science, and Co-Director of the Head and Neck Cancer Center at the University of California San Diego Moores Cancer Center.

Session: Hematology/Oncology
Catriona Jamieson, MD, PhD
Professor of Medicine, Division of Hematology/Oncology
Deputy Director, Moores Cancer Center
Koman Family Presidential Endowed Chair in Cancer Research
Chief, Division of Regenerative Medicine
Deputy Director, Sanford Stem Cell Clinical Center
UC San Diego

Catriona Jamieson, M.D., Ph.D., is Professor of Medicine in the Division of Hematology-Oncology, Deputy Director at UC San Diego Moores Cancer Center, Koman Family Presidential Endowed Chair in Cancer Research, Chief of the Division of Regenerative Medicine, Deputy Director of the Sanford Stem Cell Clinical Center, Co-Leader of the Hematologic Malignancies Program, and Director of Stem Cell Research at UC San Diego Moores Cancer Center.

Dr. Jamieson specializes in myeloproliferative disorders (MPDs) and leukemia. Myeloproliferative neoplasms are a family of uncommon but not rare degenerative disorders in which the body overproduces blood cells. Myeloproliferative neoplasms can cause many forms of blood clotting including heart attack, stroke, deep venous thrombosis, and pulmonary emboli and can develop into acute myelogenous leukemia. Although some effective treatments are available, they are laden with serious side effects. In addition, individuals can become resistant to the treatments. Dr. Jamieson studies the mutant stem cells and progenitor cells in myeloproliferative neoplasms. These cells can give rise to cancer stem cells. Cancer stem cells may lie low to evade chemotherapy and then activate again later, causing disease progression and resistance to treatment. Her goal is to find more selective, less toxic therapies.

Dr. Jamieson received her medical and doctorate degrees from the University of British Columbia. She completed her residency and clinical fellowships in bone marrow transplantation and hematology, as well as her postdoctoral research fellowship in the laboratory of Professor Irving Weissman at Stanford.

Featured Presenters

Ludmil Alexandrov, PhD
Assistant Professor of Cellular and Molecular Medicine and Bioengineering
UC San Diego

Ludmil Alexandrov is an Assistant Professor of Cellular and Molecular Medicine and Bioengineering at the University of California, San Diego. He earned his Bachelor of Science degree in Computer Science from Neumont University and received his Master’s of Philosophy in Computational Biology as well as his Ph.D. in Cancer Genetics from the University of Cambridge.

Ludmil’s research has been focused on understanding the mutational processes in cancer. In 2013, he developed the first comprehensive map of the mutational signatures in human cancer. More recently, Ludmil mapped the signatures of clock-like mutational processes operative in normal somatic cells, demonstrated that mutational signatures have the potential to be used for targeted cancer therapy, and identified the mutational signatures associated with tobacco smoking.

Ludmil has 91 publications in peer-reviewed journals from which 21 publications in Nature, Science, or Cell and another 32 publications in Nature Genetics, Nature Medicine, Cancer Cell, Science Translational Medicine, PNAS, or Nature Communications. In 2014, Ludmil Alexandrov was recognized by Forbes magazine as one of the “30 brightest stars under the age of 30”. In 2015, he was awarded the Prize for Young Scientists in Genomics and Proteomics by Science magazine and Scilifelab, and he also received a Harold M. Weintraub Award by the Fred Hutchinson Cancer Center. In 2016, Ludmil was awarded the Carcinogenesis Young Investigator Award by Oxford University Press. In 2018, Ludmil was awarded the Balfour Prize Lecture of the Genetics Society, an Alfred P. Sloan Research Fellowship
in Computational & Evolutionary Molecular Biology, and an Early Career Award by The International Academy for Medical and Biological Engineering. In 2019, Ludmil was awarded a Packard Fellowship for Science and Engineering and was named as an Abelloff V Scholar. Ludmil is currently one of six co-investigators leading the Mutographs of Cancer project, a £20 million initiative to identify the unknown cancer-causing factors.

**Fotios Asimakopoulos, MB, BChir, PhD**  
*Associate Professor in Residence, Robert J. Shillman Scholar  
Department of Medicine, Division of Blood and Marrow Transplantation  
Moore's Cancer Center, UC San Diego*

Dr. Fotios (Fotis) Asimakopoulos is Associate Professor In Residence, Robert J. Shillman Scholar at UC San Diego Department of Medicine, Division of Blood and Marrow Transplantation. He was born in Pyrgos, Peloponnese, Greece and received his Bachelor of Science degree in Cellular and Molecular Pathology from University of Bristol, United Kingdom. His Bachelor of Medicine, Bachelor of Surgery and Doctorate of Philosophy were received from University of Cambridge, United Kingdom. Following Cambridge, he served as Golda Meir Fellow at the Hebrew University of Jerusalem and Hadassah University Hospital. He then pursued a Residency in Internal Medicine at Brigham and Women's Hospital, Harvard Medical School, Boston, MA. His fellowship was completed at Memorial Sloan Kettering in New York, NY where he was a postdoctoral fellow with Nobel Prize Laureate Dr. Harold Varmus. Prior to joining the faculty as UCSD, he served as a tenure-track Assistant Professor and a tenured Associate Professor at UW-Madison. His research efforts focus on myeloma immunobiology, immunotherapy and myeloma modeling.

**Gregory Botta, MD, PhD**  
*Associate Clinical Professor of Medicine, Division of Hematology/Oncology,  
Moore's Cancer Center, UC San Diego  
Assistant Professor of Molecular Medicine, Scripps Research Translational Institute  
Department of Tumor Microenvironment & Immunology,  
Sanford Burnham Prebys Medical Discovery Institute*

Gregory Botta is a medical oncologist specializing in Gastrointestinal Tumors at the University of California San Diego Moores Cancer Center, with a research laboratory at Sanford Burnham Prebys Medical Discovery Institute. He enthusiastically joined Scripps Research Translational Institute as a KL2 Scholar to expand translational cancer treatment trials for oncology patients.

Botta has degrees in Information Systems and Biomedical Engineering from Carnegie Mellon University, where he graduated with honors. He then moved to the University of Pittsburgh, initiating graduate training as part of the Cardiac Transplant Program and Stem Cell Research Center under Stephen Winovich, Robert Kormos, MD, and Johnny Huard, PhD. He then transitioned into the joint MD/PhD program at Drexel University and the University of Pennsylvania under an NIH/NIDDK F30 Fellowship. He completed his doctoral degree in Molecular/Cellular Biology and Genetics in the labs of Peter Leikes, PhD, and Anil Rustgi, MD, regarding the mechanisms of human pancreatic cancer malignant transformation and invasion within 3D models. During this time, he was selected as an international Lindau Nobel Laureate Young Scientist.

On completion of his dual degrees, Botta joined the Scripps Clinic Research Track, completing both Internal Medicine and Oncology training at the Scripps MD Anderson Cancer Center. Currently he sees patients in Gastrointestinal Oncology at UCSD. In parallel, he continues research in pancreatic and solid tumor metabolic drug delivery, anti-metastatic studies, and immunotherapy in the laboratories of Erkki Ruoslahti, MD/PhD at Sanford Burnham Prebys National Cancer Institute and Luc Teyton, MD/PhD at Scripps Research.
James Christensen, PhD
Executive VP and Chief Scientific Officer
Mirati Therapeutics

Dr. Christensen joined Mirati in June 2013. At Mirati Therapeutics, he is responsible for drug discovery, translational research, drug manufacturing and companion diagnostics research and teams. While at Mirati, Dr. Christensen led activities related to the discovery and advancement of the KRASG12C inhibitor, MRTX849, as well as the spectrum-selective receptor tyrosine kinase (RTK) inhibitor, sitravatinib, through IND and clinical development. Prior to Mirati, Dr. Christensen most recently was the head of Oncology Precision Medicine and member of the executive leadership team in the Oncology Research Unit at Pfizer. Dr. Christensen joined Pfizer in 2003 and his responsibilities there included leading nonclinical research and translational sciences efforts for oncology programs including sunitinib (Sutent®) and crizotinib (Xalkori®). Dr. Christensen was at SUGEN/Pharmacia as a Group Leader on the Preclinical Research and Exploratory Development team where he was responsible for leadership of c-Met and erbB family preclinical development programs and aspects of research and development for sunitinib. Dr. Christensen initiated his industry experience at Warner Lambert/Parke-Davis with research focus in RTK biology and pathway biomarker development in the oncology therapeutic area. Dr. Christensen has authored or co-authored over 140 peer-reviewed research articles in scientific journals including Science, Nature, Cancer Cell, Cancer Discovery, New England Journal of Medicine and others. In addition, Dr. Christensen participates on the editorial boards for Cancer Research and Molecular Cancer Therapeutics and is a member of the Scientific Advisory panel at Bridge Bio/QED.

Dr. Christensen received his PhD degree focusing in Molecular Pharmacology from North Carolina State University with dissertation research directed toward characterization of mechanisms of apoptosis dysregulation during the process of carcinogenesis.

Peter Emtage, PhD
Global Head of Cell Therapy Research
Kite Pharma

Peter Emtage, Ph.D., serves as the Global Head of Cell Therapy Research at Kite Pharma. He is an immunologist by training and over the past twenty years has focused on developing drugs to adjust the immune response in humans. His work in oncology, autoimmunity and infectious disease has included the utilization of viral and non-viral delivery systems, chimeric antigen receptors and TCR adaptive T-cell modalities, and monoclonal antibodies in checkpoint blockade and immuno-oncology.

Prior to Kite Pharma, Dr. Emtage served as Chief Scientific Officer at Cell Design Labs Inc. and was Vice President of Synthetic Immunology at Intrexon Corporation. He has served as a member of the Scientific Advisory Board at Immunocore Therapeutics Inc. Dr. Emtage received his Ph.D. in Molecular Virology, Immunology and Inflammation at McMaster University and completed his post-doctoral fellowship at the National Institutes of Health.

William Go, MD, PhD
Senior Vice President, Head of Development
A2 Biotherapeutics

William Go, MD, PhD, is Senior Vice President and Head of Development at A2 Biotherapeutics. As head of development, his core responsibilities include overseeing process development through to clinical development, utilizing A2's novel platform technology to develop immunocellular therapy in serious diseases including cancer. Before joining A2 Biotherapeutics, Dr. Go was Vice President of Clinical Development at Kite Pharma, where he led the ZUMA-1 pivotal study and eventual FDA and EMA approvals of YESCARTA®, the first CAR T cell therapy approved in Large B Cell Lymphoma. YESCARTA received the Prix Galien Award for Best Biotechnology Product in 2018. Dr. Go then supervised the clinical development of CD19 CAT Cell in B cell malignancies.

Dr. Go received his BA in Biology from Carleton College and attended UC San Diego where he completed his MD in 2006 and was an internal medicine resident and hematology/oncology fellow. He was the recipient of the California Institute for Regenerative Medicine fellowship award and the American Association of Cancer Institutes’ fellowship award studying tumor immunology.
Zachary Hornby
CEO, President and Director
Boundless Bio

Zachary (“Zach”) Hornby has served in executive and director roles for multiple private and public biotechnology companies. Prior to joining Boundless Bio, Zach was Chief Executive Officer, President and a Director at Optera Therapeutics Corp, a company that was developing multiple clinical-stage cellular therapeutics that had been innovated at MD Anderson Cancer Center. Before that, he was Chief Operating Officer at Ignyta, where he oversaw development of the company’s portfolio of four clinical stage therapeutics and was the team leader for the company’s lead program, entrectinib, which was the first drug in pharmaceutical history to garner the coveted BTD (FDA), PRIME (EMA) and Sakigake (PMDA) designations. In that role, he also led the business development process that resulted in Ignyta’s acquisition by Roche for $1.7 billion; after the Roche acquisition, Zach served as the Ignyta site head where he was responsible for overseeing the integration into Roche. Before assuming the COO role, Zach was Ignyta’s Chief Financial Officer, helping the company go public and raise $120 million in capital. Prior to joining Ignyta, Zach served in roles of increasing responsibility across business development, marketing, new product planning, finance, and regulatory affairs at Fate Therapeutics, Halozyme Therapeutics, Neurocrine Biosciences and Transkaryotic Therapeutics (“TKT,” now the Human Genetic Therapies division within Takeda/Shire) and was a life sciences consultant at L.E.K. Consulting.

Zach holds B.S. and M.S. degrees in biology, with a concentration in neuroscience, from Stanford University and an MBA from Harvard Business School.

Danelle James, MD
Imbruvica Clinical Development Lead
Pharmacy cics, an AbbVie Company

Danelle James is Imbruvica Clinical Development Lead at Pharmacy cics. Prior to joining Pharmacy cics in 2011, Dr. James was a faculty member in the Department of Medicine, Division of Hematology and Oncology at University of California San Diego. Her research focus at UCSD for almost ten years, was the study of the Chronic Lymphocytic Leukemia (CLL) and the tumor microenvironment and the clinical-translational development of agents that can be used to target these interactions. Danelle worked closely under the mentorship of Thomas Kipps and as a member CLL Research Consortium (CRC), she co-ordinated the clinical trials program evaluating the combination of novel agents for the treatment of CLL. Danelle started her career in industry approximately 20 years ago at Biogen in Cambridge Massachusetts where she worked in the Department of Immunology and Inflammation.

Dr. James completed Internal Medicine residency and Hematology/Oncology fellowship at UCSD, is Board Certified in Internal Medicine and in Hematology. She obtained formal education in clinical research methodologies and a Masters degree in Advanced Studies of Clinical Research from UCSD.

Aaron Miller, MD, PhD
Assistant Clinical Professor of Medicine, Division of Hematology/Oncology
Department of Medicine, Moores Cancer Center, UC San Diego

Aaron M. Miller, MD, PhD, is a board certified medical oncologist who specializes in diagnosing and treating gastrointestinal cancers. Dr. Miller's approach to care emphasizes personalized medicine/precision oncology, adoptive cellular therapy, next-generation tumor sequencing and tumor immunology. He is part of the gastrointestinal cancer unit at Moores Cancer Center at UC San Diego Health, where he works alongside a multidisciplinary team to provide patients with highly specialized care.

Dr. Miller is an assistant professor in the Department of Medicine, where he instructs medical students, residents and fellows at UC San Diego School of Medicine. He holds a joint faculty appointment at the La Jolla Institute for Allergy and Immunology and is actively involved in cancer research, with the aim of translating his discoveries in the lab into new ways of treating patients.

Dr. Miller completed a fellowship in hematology-oncology at UC San Diego School of Medicine, along with a residency in internal medicine. He earned his medical degree from the Feinberg School of Medicine and a doctoral degree from the Graduate School, both at Northwestern University. He is a member of numerous professional organizations, including the American Society of Clinical Oncology, the American Association for Cancer Research.
and the American Medical Association.

Michael Pellini, MD  
**Managing Partner**  
**Section 32**

Mike is a Managing Partner of Section 32, a venture capital fund investing at the frontiers of technology, healthcare and life sciences. Previously, he served as CEO of Foundation Medicine (NASDAQ:FMI), a company which transformed the way pharmaceutical companies and physicians evaluate the genomic changes underlying a patient's cancer, until he transitioned to chairman through the close of Roche's (NASDAQ:RHHBY) acquisition of FMI in August 2018. Previously, he was President and COO of Clarient (NASDAQ:CLRT), a national leader in molecular pathology, which was acquired by GE Healthcare in 2010.

He currently serves as a member of the Board of Directors for Tango Therapeutics, Nusano, Vineti, Singular Genomics, Adaptive Biotechnologies, Octave Health, Thrive Earlier Detection, Sema4, the Personalized Medicine Coalition, and the Mission Hospital Foundation (Providence/St. Joseph Health). Dr. Pellini brings a breadth of understanding in personalized medicine, with a particular interest and focus on defeating cancer. He is also a member of the President's Leadership Council at Thomas Jefferson University and Jefferson Health, as well as the Advisory Board for Mission Hospital's Cancer Institute (Providence/St. Joseph Health).

Dr. Pellini received a BA from Boston College, an MBA from Drexel University and an MD from Jefferson Medical College.

Ivor Royston, MD  
**Chief Executive Officer**  
**Viracta Therapeutics**

Dr. Royston is the President and CEO of Viracta Therapeutics, a San Diego-based biotechnology company focused on novel therapies for viral-associated cancers. Previously, Dr. Royston was a Managing Partner (1990-2017) of Forward Ventures, a San Diego specialized life science venture capital firm, and the founding President and CEO of the Sidney Kimmel Cancer Center (1990-2000). Prior to the above, he was Director of Clinical Immunology of the University of California, San Diego. Cancer Center. Dr. Royston was the co-founder of Hybritech, Inc., San Diego's first biotechnology company, which developed the PSA test for prostate cancer; and the co-founder of IDEC Corporation, which developed the first monoclonal antibody therapy for cancer, and which subsequently merged with Biogen to form Biogen Idec, now Biogen [NASDAQ: BBIIB].

Dr. Royston has been instrumental in the formation, financing, and development of numerous biotechnology companies. Today, he serves on the boards of Biocept [NASDAQ:BCPT] and Viracta.

Dr. Royston received his B.A. and M.D. degrees from Johns Hopkins University and completed post-doctoral training in internal medicine and medical oncology at Stanford University. Dr. Royston's honors include the San Diego Entrepreneur of the Year Award, the appointment by President Clinton to a six-year term on the National Cancer Advisory Board, and the induction into the San Diego Entrepreneur Hall of Fame.

Cynthia Rubenstein, PhD  
**Loxo Oncology, a wholly owned subsidiary of Eli Lilly and Company**

Cynthia Rubenstein received her PhD in Cancer Biology from the University of Arizona. After completion of her graduate studies Cynthia joined Genoptix as a Medical Science Liaison where she took part in managing relationships with key health care professionals through scientific support for research initiatives (IIS/clinical trials), publications, conference presentations, consulting agreements and other medical affairs endeavors. In 2018, Cynthia joined Loxo Oncology as a Diagnostic Medical Science Liaison covering the West Coast. Since joining the team Cynthia has established relationships with molecular pathologists and has presented to wide audiences on the utility of molecular diagnostic assays for the identification of patients who may benefit from targeted therapies.
Stephen P. Schoenberger, PhD  
*Professor, Laboratory of Cellular Immunology, La Jolla Institute for Immunology  
Director of Translational Science, San Diego Center for Precision Immunotherapy  
Adjunct Professor, Division of Hematology and Oncology, School of Medicine, UC San Diego*

Stephen P. Schoenberger is a translational immunologist working in the area of precision cancer immunotherapy. Leveraging insights made over more than 20 years of fundamental studies on the immunobiology of CD4+ and CD8+ T cells, he now guides an integrated research consortium involving research scientists, physicians, and bioinformaticians working to identify patient-specific natural ligands for neoantigen-specific T cells. Clinical trials aimed at targeting these through personalized cancer vaccines and adoptive cellular therapy are being evaluated in two independent clinical trials now underway at the UCSD Moores Cancer Center, with additional IITs scheduled for 2020.

Hervé Tiriac, PhD  
*Associate Project Scientist, Department of Surgery  
Moores Cancer Center, UC San Diego*

Dr. Tiriac received his Ph.D. from UC San Diego studying pre-mRNA splicing and transcription with Dr. Tracy Johnson. Dr. Tiriac performed his post-doctoral work in the laboratory of Dr. David Tuveson at Cold Spring Harbor Laboratory where he focused his efforts on developing pancreatic cancer organoids from patients of all stages. Dr. Tiriac now works at UC San Diego within the department of Surgery where he is continuing his precision medicine research using advanced patient-derived models.

Bob Valamehr, PhD, MBA  
*Chief Development Officer  
Fate Therapeutics*

Bob Valamehr is the Chief Development Officer at Fate Therapeutics, overseeing the company’s early development activities including “off-the-shelf” cell therapy product candidates derived from the company’s induced pluripotent stem cell platform. Previously, Dr. Valamehr was the Vice President of Cancer Immunotherapy at Fate and prior to that played key scientific roles at Amgen, the Center for Cell Control (a NIH Nanomedicine Development Center) and the Broad Stem Cell Research Center developing novel methods to control pluripotency, to modulate stem cell fate including hematopoiesis and to better understand cellular signaling pathways associated with cancer. He has co-authored numerous studies and patents related to stem cell biology, oncology and materials science. Dr. Valamehr received his Ph.D. from the Department of Molecular and Medical Pharmacology at UCLA, his M.B.A. from Pepperdine University and his B.S. from the Department of Chemistry and Biochemistry at UCLA.